Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Granted FDA Fast Track Designation
Go back to Biogen’s Investigational Alzheimer’s Disease Treatment Aducanumab Granted FDA Fast Track Designation| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 223.95 +1.28 (0.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $222.67 | 52 Week High | $333.65 | |||
| Open | $225.44 | 52 Week Low | $223.02 | |||
| Day High | $225.80 | P/E | 28.67 | |||
| Day Low | $221.23 | EPS | $7.81 | |||
| Volume | 203,584 | |||||
